Similarly, NOTCH1-mutant HNSCC shows sensitivity to PI3K/mTOR inhibition, and CDKN2A-altered tumors may benefit from CDK4/6 inhibition [45,67]. This evidence concerns the gene PIK3CA and head and neck squamous cell carcinoma.